14. HIV Researchers and Advocates Killed in Plane Crash En Route to AIDS Conference

The 2014 International AIDS Conference in Melbourne got off to a somber start in July after several HIV researchers and advocates en route to the meeting were killed on Malaysian Airlines flight MH17 from Amsterdam to Kuala Lumpur, which crashed after being hit by a missile near the Russia-Ukraine border.

Read more:

Previous Conferences

The Liver Meeting (AASLD 2014) 
November 7-11, 2014, Boston

HIV Drug Therapy 2014 
November 2-6, 2014, Glasgow

HIV Research for Prevention (HIVR4P 2014)
October 28-31, 2014, Cape Town

IDWeek 2014 
October 8-12, 2014, Philadelphia

54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014)
September 5-9, 2014, Washington, DC

20th International AIDS Conference (AIDS 2014) 
July 20-25, 2014, Melbourne

Digestive Disease Week 2014
May 3-6, 2014, Chicago

49th International Liver Congress (EASL 2014) 
April 9-13, 2014, London

2014 Conference on Retroviruses and Opportunistic Infections (CROI 2014) 
March 3-6, 2014, Boston

The Liver Meeting (AASLD 2013) 
November 1-5, 2013, Washington, DC

14th European AIDS Conference (EACS 2013) 
October 16-19, 2013, Brussels

IDWeek 2013 
October 2-6, 2013, San Francisco

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) 
September 10-13, 2013, Denver

7th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2013) 
June 30-July 3, 2013, Kuala Lumpur

Digestive Disease Week 2013 
May 18-21, 2013, Orlando

48th International Liver Congress (EASL 2013) 
April 24-28, 2013, Amsterdam

20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) 
March 3-6, 2013, Atlanta

11th International Congress on Drug Therapy in HIV Infection (HIV11)
November 11-15, 2012, Glasgow

The Liver Meeting (AASLD 2012)
November 9-13, 2012, Boston

52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)
September 9-12, 2012, San Francisco

XIX International AIDS Conference (AIDS 2012)
July 22-27, 2012, Washington, DC

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
March 5-8, 2012, Seattle

The Liver Meeting (AASLD 2011)
November 4-8, 2011, San Francisco

49th Annual Meeting of the Infectious Disease Society of America (IDSA 2011)
October 20-23, 2011, Boston

13th European AIDS Conference (EACS 2011)
October 12-15, 2011, Belgrade

51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011)
September 17-20, 2011, Chicago

6th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2011)
July 17-20, 2011, Rome

46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011)
March 30-April 3, 2011, Berlin

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
February 27-March 2, 2011, Boston

The Liver Meeting (AASLD 2010)
October 29-November 3, 2010, Boston

50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010)
September 12-15, 2010, Boston

XVIII International AIDS Conference (AIDS 2010)
July 18-23, 2010, Vienna

IAS 2013: Adolescents with HIV Face Challenges Transitioning to Adulthood [VIDEO]

Worldwide, a growing number of people infected with HIV as infants or young children and treated with antiretroviral therapy for many years are now reaching adulthood and face a challenging transition, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

Read more:

IAS 2011: Inflammation Markers Linked to Liver Disease, Death in HIV/HBV and HIV/HCV Coinfection

Various blood biomarkers associated with immune activation and inflammation predicted liver flares, fibrosis progression, and death among HIV positive people coinfected with hepatitis B or C, according to 2 studies presented last month at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome.

Read more:

AIDS 2012 Conference Program Now Online, Global Village Events Free

The full program for the XIX International AIDS Conference (AIDS 2012) was announced this week and is now available online at www.aids2012.org. Abstracts, slides, posters, and webcasts of selected presentations will also added to the website throughout the meeting.

Read more:

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)

HIV/AIDS Articles

• Can Lowering Community Viral Load Decrease New HIV Infections?
• Positive Pulse: Expert Commentaries From CROI 2011*
• HPV and Anal Cancer Research at CROI 2011
• HIV Enters and Injures Brain Early
• Vitamin D May Reduce Tenofovir-related Bone Loss
• Do Black Patients Respond Less Well to Antiretroviral Therapy?
• Immediate ART Improves Survival for HIV+ People with TB
• Reduced Limb Muscle, More Belly Fat Linked to Higher Mortality
• Studies Shed Further Light on Cardiovascular Disease among People with HIV
• Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz
• Longer Preventive Therapy, More Drugs Reduce Risk of Mother-to-Child HIV Transmission
• Experimental Integrase Inhibitor Dolutegravir Looks Promising for People with Resistant HIV
• Is Bone Loss Related to Immune Reconstitution in People on ART?
• New Tenofovir Pro-drug GS-7340 Looks Good in Early Study
• 5 Drugs No Better than 3 for Treatment of Primary HIV Infection
• Long-term Benefits of Circumcision for HIV Prevention
• No More Science Fiction -- HIV Gene Therapy Delivers
• Once-daily Raltegravir Found Less Effective than Twice-Daily Dosing
• HIV Attachment Inhibitor BMS-663068 Shows Good Activity in Phase 2a Trial
• Researchers Report Further Findings from iPrEx PrEP Trial
• Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
• FDA Safety Review Does Not Find Abacavir-Heart Attack Link
• International AIDS Society Launches International HIV Cure Working Group

HIV/HCV and HIV/HBV Coinfection Articles

• HCV Re-infection Common among HIV+ Gay Men in Amsterdam
• HIV/HCV Coinfected People Have Higher Risk of Bone Loss
• Acute Hepatitis C Treatment for HIV/HCV Coinfected People
• Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir
• Liver Fibrosis Raises Risk of Kidney Impairment in HIV/HBV Coinfected Patients on Tenofovir
• Little Overlap of Sexually Transmitted HCV between U.S. and Europe
• More Liver-related Death for HIV/HBV than HIV/HCV Coinfection in MACS Cohort
• Telaprevir Improves Treatment Outcomes for HIV/HCV Coinfected People

Library of Slides and Posters

• Success of Test and Treat in San Francisco? Reduced Time to VirologicSuppression, Decreased Community Viral Load, and Fewer New HIV Infections, 2004 to 2009
  M Das and others. CROI 2011.
• Use of Community Viral Load as Population-Based Biomarker of HIV „Ÿ Washington, DC, 2004 . 2008
  A Castel and others. CROI 2011.
• Disparities in Community Viral Load among HIV Infected Persons in NYC
  F Laraque and others. CROI 2011.
• HIV is Associated with Clinically Confirmed Myocardial Infarction after Adjustment for Smoking and Other Risk Factors
  M Freiberg and others. CROI 2011.
• Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members
  D Klein and others. CROI 2011.
• No Association of Myocardial Infarction with Abacavir Use: Findings of an FDA Meta-analysis
  X Ding and others. CROI 2011.
• Raltegravir (RAL) Demonstrates Durable Virologic Suppression and Superior Immunologic Response with a Favorable Metabolic Profile Through 3 Years Treatment (Tx): 156 Week (Wk) Results from STARTMRK
  J Rockstroh and others. CROI 2011.
• ARIEL: 24-week safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients aged 3 to <6 years
  A Violari and others. CROI 2011.
• Pharmacokinetic Parameters of Once-Daily TMC278 Following Administration of Efavirenz in Healthy Volunteers
  H Crauwels and others. CROI 2011.
• Lipid profiles of TMC278 and efavirenz in treatment-naïve, HIV-1-infected patients: pooled Week 48 data from the randomized, double-blind, Phase III ECHO and THRIVE trials
  J Arribas and others. CROI 2011.
• Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks
  A Mills and others. CROI 2011.
• Change in Vitamin D Levels Smaller and Risk of Development of Severe Vitamin D Deficiency Lower Among HIV-1-Infected, Treatment-naïve Adults Receiving TMC278 Compared with Efavirenz: 48-week Results from the Phase III ECHO Trial
  D Wohl and others. CROI 2011.
• GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir DisoproxilFumarateDuring 14 Days of Monotherapyin HIV-1 Infected Subjects
  A Diamond and others. CROI 2011.
• No Association of Myocardial Infarction with ABC Use: An FDA Meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections
  X Ding and others. CROI 2011.

EASL 2012: Boceprevir Improves Cure Rates for HIV/HCV Coinfection but Beware of Drug Interactions

Adding boceprevir (Victrelis) to pegylated interferon and ribavirin for treatment of chronic hepatitis C in people with HIV substantially increased the likelihood of end-of-treatment response and sustained response 12 weeks after completing therapy, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.

Read more:

Coverage of the 46th Annual Meeting of the European Association for the Study of the Liver

March 30 - April 3, 2011, Berlin, Germany

The material posted on HIVandHepatitis.com is not approved by nor is it a part of EASL 2011.

Hepatitis C Articles

• EASL Releases New Hepatitis C Clinical Practice Guidelines
• Boosted ABT-450 Improves Early Response to Interferon for Hepatitis C
• Tegobuvir Works Well in Triple and Quad Regimens for HCV
• Boosted Danoprevir Improves Response in Prior Null Responders
• Once-Daily BI201335 Ups Response to Interferon for Hepatitis C
• BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
• Statin Boosts Response to Pegylated Interferon/Ribavirin
• Boceprevir Helps Hepatitis C Patients with Cirrhosis
• TMC435 Beats Standard Therapy Regardless of HCV Genotype
• Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
• Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
• Pegylated Interferon Lambda Boosts Response with Few Side Effects
• First Sustained Response Data for Polymerase Inhibitor Mericitabine
• 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
• Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
• BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
• Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab

Hepatitis B Articles

• Kidney Toxicity Uncommon among People Taking Tenofovir for Hepatitis B
• HBV Genotype Predicts HBeAg Seroconversion on Tenofovir
• Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B

Library of Slides and Posters

• Baseline Genotype And HBsAg Were Found To Have Signifi cant Association With HBeAg Seroconversion Following Up To 4 Years Of Tenofovir Disoproxil Fumarate Treatment
  J Heathcote and others. EASL 2011.
• Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist
  D Tumas and others. EASL 2011.
• Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
  R Lanford and others. EASL 2011.
• Anti-Viral Effi cacy and Induction of an Antibody Response Against Surface Antigen with the TLR7 Agonist GS-9620 in the Woodchuck Model of Chronic HBV Infection
  S Menne and others. EASL 2011.
• Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon a-2a and Ribavirin in the PILLAR Study
  J Aerssens and others. EASL 2011.
• Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin
  O Lenz and others. EASL 2011.
• Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment
  V Sekar and others. EASL 2011.
• The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis
  S Zeuzem and others. EASL 2011.
• First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects
  S Pol and others. EASL 2011.
• A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
  E Lawitz and others. EASL 2011.
• Interim Results of a Randomized Treatment Study of Emtricitabine/Tenofovir DF (FTC/TDF) and HBIG Withdrawal in Post-Orthotopic Liver Transplant (OLT) Recipients for CHB
  L Tepperman and others. EASL 2011.
• Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451
  A Corsa and others. EASL 2011.
• Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA) Assessments in Patients with Chronic Hepatitis B (CHB)
  S Fung and others. EASL 2011.
• Effects of Tenofovir DF on Renal Function of Chronic HBV Patients in Three Global Randomized Studies
  P Marcellin and others. EASL 2011.
• A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects
  U Lopatin and others. EASL 2011.
• HBsAg Kinetics in Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumurate (TDF) for up to 4 years
  P Marcellin and others. EASL 2011.